Project Grant F31CA295111
Award Date 12/1/25
Completion Date 6/30/27
Dollars Obligated $105K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Minnesota, USA
Similar Awards
- The National Cancer Institute awarded a $148,050 Project Grant under the Cancer Research Manpower federal grant program (CFDA 93.398) to Weill Medical College of Cornell University. The grant supports research to study the role of the APOBEC3 family of cytosine deaminases in driving genomic instability and mutagenesis in lung cancer. The project aims to identify the specific APOBEC3 enzymes responsible for lung cancer mutagenesis and develop novel tools to measure APOBEC3 activity. This research...
- The U.S. National Cancer Institute (NCI) awarded a $395,973 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Regents of the University of Minnesota to support the development of deazaflavin analogs as potent and selective inhibitors of the MRP1 transporter for cancer chemosensitization. The project aims to screen and characterize a library of deazaflavin compounds to identify lead candidates that can effectively inhibit MRP1-mediated multidrug resistance, thereby...
- This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $221,456.00 to the Regents of the University of Minnesota to develop and optimize a novel approach for enriching microbes from clinical cancer samples. The goal is to enable deep metaproteomic analysis and characterize the functional proteins contributed by microbes that influence the tumor microenvironment during cancer development. The project will pursue two specific...
- The National Cancer Institute awarded a $119,858 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Regents of the University of Minnesota, Office of Sponsored Projects Administration. The award supports research to elucidate mechanisms governing immune surveillance and resistance to antitumor T cell response in pancreatic cancer. The project aims to identify ways to safely promote T cell-mediated destruction of pancreatic cancer through combinatorial immunotherapies....
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $150,878 to the Regents of the University of Minnesota (doing business as the Office of Sponsored Projects Administration) to support research on tissue-resident adaptive CD56bright natural killer (NK) cell responses in cancer. The key objectives are to advance the understanding of the functions of CD56bright "bright-tank" NK cell populations in tumors and identify mechanisms...
- This $580,238 federal Project Grant was awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the Regents of the University of Minnesota on January 10, 2025. The grant will fund a 5-year research project to investigate novel blood biomarkers that could predict the early development of hepatocellular carcinoma (liver cancer) in Hispanic individuals infected with the hepatitis B virus. The research aims to develop a non-visual screening approach...
- This $113,937 federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) to the Regents of the University of Minnesota, Office of Sponsored Projects Administration, is funding research to identify methods for harnessing the potential of "bystander" T cells to develop new cancer immunotherapies. The project aims to explore how bystander T cells, which are not specific to tumor antigens, can be activated within the tumor microenvironment to...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $544,768 to the University of New Mexico to conduct research focused on understanding the fundamental biological mechanisms of human papillomavirus (HPV)-induced tumors and precancerous lesions. The award aims to elucidate how inhibition of the MEK/ERK signaling pathway can lead to regression of HPV-driven tumors, with the goal of advancing scientific knowledge that can enable improved...
- The University of California, San Diego (UCSD) was awarded a $444,952 Project Grant by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to conduct research exploring the impact of base deaminase deregulation on precancer evolution. The 5-year grant, which commenced on December 1, 2024, aims to elucidate the relative roles of APOBEC3C and ADAR1 deaminases in driving the progression of myeloproliferative neoplasms (MPNs) to secondary acute myeloid leukemia (sAML). The research...
- The Department of Health and Human Services' National Cancer Institute has awarded a $128,199 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to the Regents of the University of Michigan. The grant, titled "Deciphering the Functional Role of PPP2R1A Mutations in Cancer," aims to evaluate the functional impact of mutations in the PPP2R1A gene, which encodes the alpha isoform of the A subunit of the protein phosphatase 2A (PP2A) tumor suppressor....